Treatment of RAF1-Related Biventricular Hypertrophy and Double Chamber Right Ventricle by MEK Inhibition Using Trametinib

. 2025 Jan;92(1):93.

doi: 10.1007/s12098-024-05305-9. Epub 2024 Oct 28.

Stasa Krasic^{1

2}, Ivana Đuric¹, Nikola Ilic³, Adrijan Sarajlija^{2

3}, Dejan Nesic⁴, Vladislav Vukomanovic^{5

6}

Affiliations

¹ Department of Cardiology, Mother and Child Health Institute of Serbia, Belgrade, Serbia.
² Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
³ Clinical Genetics Outpatient Clinic, Mother and Child Health Institute of Serbia, Belgrade, Serbia.
⁴ Faculty of Medicine, Institute of Medical Physiology, University of Belgrade, Visegradska 26/II, Belgrade, RS, 11129, Serbia.
⁵ Department of Cardiology, Mother and Child Health Institute of Serbia, Belgrade, Serbia. vvukomanovicdr@gmail.com.
⁶ Faculty of Medicine, University of Belgrade, Belgrade, Serbia. vvukomanovicdr@gmail.com.

Stasa Krasic et al. Indian J Pediatr. 2025 Jan.

. 2025 Jan;92(1):93.

doi: 10.1007/s12098-024-05305-9. Epub 2024 Oct 28.

Stasa Krasic^{1

2}, Ivana Đuric¹, Nikola Ilic³, Adrijan Sarajlija^{2

3}, Dejan Nesic⁴, Vladislav Vukomanovic^{5

6}

¹ Department of Cardiology, Mother and Child Health Institute of Serbia, Belgrade, Serbia.
² Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
³ Clinical Genetics Outpatient Clinic, Mother and Child Health Institute of Serbia, Belgrade, Serbia.
⁴ Faculty of Medicine, Institute of Medical Physiology, University of Belgrade, Visegradska 26/II, Belgrade, RS, 11129, Serbia.
⁵ Department of Cardiology, Mother and Child Health Institute of Serbia, Belgrade, Serbia. vvukomanovicdr@gmail.com.
⁶ Faculty of Medicine, University of Belgrade, Belgrade, Serbia. vvukomanovicdr@gmail.com.

No abstract available

Conflict of interest statement

Declarations. Conflict of Interest: None.

1. Saint-Laurent C, Mazeyrie L, Yart A, Edouard T. Novel therapeutic perspectives in Noonan syndrome and RASopathies. Eur J Pediatr. 2024;183:1011–9. - DOI - PubMed
1. Gazzin A, Fornari F, Cardaropoli S, et al. Exploring new drug repurposing opportunities for MEK inhibitors in RASopathies: a comprehensive review of safety, efficacy, and future perspectives of trametinib and selumetinib. Life. 2024;14:731. - DOI - PubMed - PMC
1. Andelfinger G, Marquis C, Raboisson MJ, et al. Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition. J Am Coll Cardiol. 2019;73:2237–9. - DOI - PubMed - PMC